medigraphic.com
ISSN 1527-3172 (Electronic)

2017, Number 2-3

<< Back Next >>

MEDICC Review 2017; 19 (2-3)

Cuban exogenous pulmonary surfactant in treatment of pediatric acute respiratory distress syndrome

Rodríguez-Moya VS, Machado-Lubián MC, Barrese-Pérez Y, Ávila-Albuerne Y, Uranga-Piña R, Blanco-Hidalgo O, Díaz-Casañas E

Language: English
References: 49
Page: 24-31
PDF size: 259.99 Kb.


ABSTRACT

Introduction Acute respiratory distress syndrome is a complex heterogeneous disorder with low incidence but high case fatality in children. Treatment with pulmonary surfactants is a possible option. Surfacen, a Cuban exogenous pulmonary surfactant, has been proven safe and effective in premature newborns with hyaline membrane disease, but evidence regarding its efficacy in older children is still inconclusive.
Objective Determine Surfacen’s efficacy in improving oxygenation and increasing survival in children with acute respiratory distress syndrome.
Methods A multicenter (five pediatric intensive care units in four provinces), open-label, controlled, randomized phase III clinical trial with two treatment groups was conducted from November 2009 through August 2013, with 19 girls and 23 boys aged 1 month to 18 years. The experimental group (20 patients) received conventional treatment (oxygenation and mechanical ventilation) plus intratracheal instillation of Surfacen (100 mg/4 mL) every eight hours for three days. The control group (22 patients) received only conventional treatment. The primary dependent outcome was patient vital status (alive or deceased) 28 days after study enrollment. Other variables and outcomes analyzed were age, sex, ARDS presentation, Kirby index (arterial oxygen tension over inspired oxygen fraction), oxygenation index, static lung compliance, transcutaneous oxygen saturation, radiographic course, mechanical ventilation time and length of stay in neonatal intensive care. Statistical tests used were the chi-square test and Fisher exact test.
Results On day 28, there was 80% survival in the experimental group versus 38.1% in the control group. There were significant differences between the experimental and the control group in Kirby index, oxygenation index, static lung compliance and radiographic course, all favoring the experimental group. For every 2.38 patients treated in total, there was one additional survivor in the experimental group.
Conclusions When combined with conventional therapy in the regimen employed, Surfacen improves oxygenation and increases survival in children with ARDS.


REFERENCES

  1. Pediatric Acute Lung Injury Consensus Conference Group. Pediatric acute respiratory distress syndrome: consensus recommendations from the Pediatric Acute Lung Injury Consensus Conference. Pediatr Crit Care Med. 2015;16(5 Suppl 1):428–39.

  2. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet [Internet]. 1967 Aug 12 [cited 2016 Jan 12];290(7511):319–23. Available from: http:// www.sciencedirect.com/science/article/pii/ S0140673667901687

  3. Hodgson CL, Tuxen DV, Davies AR, Bailey MJ, Higgins AM, Holland AE, et al. A randomised controlled trial of an open lung strategy with staircase recruitment titrated PEEP and targeted low airway pressures in patients with acute respiratory distress syndrome. Crit Care [Internet]. 2011[cited 2016 Apr 27];15(3):R133. Available from: http://www.biomedcentral.com/content/pdf/ cc10249.pdf

  4. García-Fernández J, Canfrán S, Gómez de Segura IA, Suárez-Sipmann F, Aguado D, Hedenstierna G. Pressure safety range of barotrauma with lung recruitment manoeuvres. Eur J Anaesthesiol [Internet]. 2013 Sep [cited 2016 Apr 27];30(9):567–74. Available from: http:// journals.lww.com/ejanaesthesiology/Abstract /2013/09000/Pressure_safety_range_of_baro trauma_with_lung.9.aspx

  5. Raghavendran K, Willson D, Notter RH. Surfactant therapy of ALI and ARDS. Crit Care Clin [Internet]. 2011 Jul 1[cited 2016 Jan 12];27(3):525–59. Available from: http://www .ncbi.nlm.nih.gov/pmc/articles/PMC3153076/

  6. Willson DF, Thomas NJ, Tamburro R, Truemper R, Truwit J, Conaway M, et al. Pediatric Calfactant® in acute respiratory distress syndrome trial. Pediatr Crit Care Med [Internet]. 2013 Sep [cited 2016 Jan 12];14(7):657–65. Available from: http://www .intensivo.sochipe.cl/subidos/catalogo3/Calfac tante%20en%20SDRA%20PCCM%202013.pdf

  7. Willson DF, Thomas NJ, Markovitz BP, Bauman LA, DiCarlo JV, Pon S, et al. Effect of exogenous surfactant (Calfactant®) in pediatric acute lung injury: a randomized controlled trial. JAMA [Internet]. 2005 Jan 26 [cited 2016 Apr 27];293(4):470–6. Available from: http://jama .jamanetwork.com/article.aspx?articleid=200218 &resultclick=1

  8. Moreno Vásquez O, Lee López M, Domínguez Dieppa F, Pascual López MA, Alonso Abad AL, Jiménez Rivero G, et al. Estudio de la efi cacia del Surfacen® en el distress respiratorio del recién nacido. Rev Cubana Pediatr [Internet]. 1999 Apr– Jun [cited 2016 Apr 27];71(2):60–71. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75311999000200002&lng= es&nrm=iso&tlng=es. Spanish.

  9. Morilla Guzmán AA, Díaz Casañas E, Debesa García F, Fernández Limia O. Efectividad del SURFACEN® en neonatos prematuros con síndrome de difi cultad respiratoria. Rev Cubana Farm [Internet]. 2015 [cited 2016 Apr 27];49(3):502–11. Available from: http://scielo .sld.cu/pdf/far/v49n3/far10315.pdf. Spanish.

  10. Morilla-Guzmán AA, Díaz-Casañas E, Fernández- Limia O, Ávila-Albuerne Y, Barrese-Pérez Y. Uso de surfactante porcino en recién nacidos pre términos con bronconeumonía de inicio temprano. Rev Arch Médico Camagüey [Internet]. 2015 [cited 2016 Apr 27];19(4):[about 7 pages]. Available from: http://www.revistaamc.sld.cu/ index.php/amc/article/view/3787. Spanish.

  11. National Health Statistics and Medical Records Division (CU). Anuario Estadístico de Salud 2015 [Internet]. Havana: Ministry of Public Health (CU); 2016 [cited 2016 Sep 27]. 206 p. Available from: http://fi les.sld.cu/dne/fi les/2016/04/Anuario _2015_electronico-1.pdf. Spanish.

  12. Blanco-Hidalgo O, Cruz-Rodríguez A, Ospina- Ramírez OL, López-Rodríguez E, Vázquez- Martínez L, Pérez-Gil J. Interfacial behavior and structural properties of a clinical lung surfactant from porcine source. Biochim Biophys Acta [Internet]. 2012 Nov [cited 2016 Apr 27];1818(11):2756–66. Available from: http:// www.sciencedirect.com/science/article/pii/ S0005273612002210

  13. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika [Internet]. 1983 Dec [cited 2017 Mar 8];70(3):659−63. Available from: http://eclass.uoa.gr/modules/ document/fi le.php/MATH301/PracticalSession3/ Lan_DeMets_1983.pdf

  14. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Boca Raton: Chapman and Hall/CRC; 1999 Sep

  15. 416 p. 15. East-6, Statistical software for the design, simulation and monitoring clinical trials. User manual [Internet]. Cambridge: Cytel Inc.; 2016 [cited 2017 Mar 8]. Available from: http://www.cytel. com/software/east#section_east

  16. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS. Defi nitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med [Internet]. 1994 Mar 1 [cited 2016 Jan 12];149 (3Pt 1):818–24. Available from: http://www.atsjournals.org/doi/abs/10.1164/ ajrccm.149.3.7509706?url_ver=Z39.88-2003 &rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3 dpubmed

  17. European Agency for the Evaluation of Medicinal Products. CPMP/EWP/504/97. Committee for proprietary medicinal products. Points to consider on clinical investigation of medicinal products in the treatment of patient with acute respiratory distress syndrome. London: European Agency for the Evaluation of Medicinal Products;1997.

  18. Manzanares Tapia D, Díaz Casañas E, Alfonso Lorenzo WC, Escobar Medina AC, Colomé Dagnesses H, Muñoz Pérez MC, et al, inventors; Centro Nacional de Sanidad Agropecuaria, assignee. Surfactante pulmonar natural de origen porcino. Republic of Cuba patent CU A61K 35/42. 1997. Spanish.

  19. Blanco-Hidalgo O, Beltrán-Núñez A, González- Rodríguez D, Sánchez-Calero J, Fernández- Limia O, Faure-García R, et al. Some Anti-Infl ammatory Properties of a Natural Pulmonary Surfactant: SURFACEN®. ACP. 2000;9(3):201–2.

  20. Blanco-Hidalgo O, Riverón-Alemán Y, de Armas- Sanabria E, Sánchez-Calero J, Faure-García R, Fernández-Limia O. SURFACEN® inhibe el crecimiento de bacterias causantes de infecciones respiratorias. Biotecnol Aplicada [Internet]. 2005 [cited 2016 Apr 27];22(4):279–81. Available from: http://elfosscientiae.cigb.edu.cu/PDFs/Biotec nol%20Apl/2005/22/4/BA002204OC279-281 .pdf. Spanish.

  21. National Drugs Quality Control Center (CU). Expediente de Registro Sanitario de Surfacen® (No. 0800). Obtenido en 1995; última renovación 2016. Havana: National Drugs Quality Control Center (CU); 2016. Spanish.

  22. Sánchez-Mendiola M, Martínez-Natera OC, Herrera-Maldonado N, Ortega-Arroyo J. Estudio controlado del tratamiento de la enfermedad de membrana hialina del recién nacido pretérmino con surfactante pulmonar exógeno (porcino vs bovino). Gac Méd Mex [Internet]. 2005 Jul–Aug [cited 2016 Apr 27];141(4):267– 71. Available from: http://www.scielo.org .mx/scielo.php?pid=S0016-3813200500 0400003&script=sci_arttext&tlng=pt. Spanish.

  23. Barrese Pérez Y, Hidalgo Sánchez AO, Albuerne Ávila Y, Uranga Piña R, Díaz Casañas E, Fernandez Limia O. Seguridad del tratamiento con surfactante pulmonar en el síndrome de difi cultad respiratoria aguda en adultos. AMC [Internet]. 2015 [cited 2016 Apr 27];19(6):551–8. Available from: http://www.revistaamc.sld.cu/ index.php/amc/issue/view/88. Spanish.

  24. Esteban A, Fernández-Segoviano P, Frutos- Vivar F, Aramburu JA, Nájera L, Ferguson ND, et al. Comparison of clinical criteria for the acute respiratory distress syndrome with autopsy fi ndings. Ann Intern Med [Internet]. 2004 Sep 21 [cited 2016 Apr 27];141(6):440–5. Available from: https://www.researchgate.net/profi le/ Niall_Ferguson/publication/8332494_Compari son_of_clinical_criteria_for_the_acute_respira tory_distress_syndrome_with_autopsy_fi ndings/ links/004635168343f05052000000.pdf

  25. Barrese-Pérez Y, Hidalgo-Sánchez AO, Albuerne- Ávila Y, Uranga-Piña R, Díaz-Casañas E, Fernández-Limia O. Surfactante pulmonar exógeno en adultos con síndrome de difi cultad respiratoria aguda. Neumol Cir Torax [Internet]. 2015 Jul–Sep [cited 2016 Apr 27];74(3):172–8. Available from: http://www.scielo.org.mx/scielo. php?script=sci_arttext&pid=S0028-37462015 000300002&lng=es&nrm=iso&tlng=es. Spanish.

  26. Ministry of Public Health (CU); National Drugs Quality Control Center (CU). Directrices sobre Buenas Prácticas Clínicas en Cuba [Internet]. Havana: ECIMED; 2000 [cited 2014 Aug 8]. Available from: http://www.cecmed.cu/sites/ default/fi les/adjuntos/reglamentacion/Dir_BPC .pdf. Spanish.

  27. World Medical Association. Declaración de Helsinki de la AMM. Principios éticos para las investigaciones médicas en seres humanos [Internet]. Ferney-Voltaire (FR): World Medical Association; 1964 Jun [cited 2014 Aug 8]. 9 p. Available from: http://www.isciii.es/ISCIII/es/contenidos/fd-inves tigacion/fd-evaluacion/fd-evaluacion-etica-in vestigacion/Declaracion-Helsinki-2013-Esp.pdf. Spanish.

  28. Cuban Public Registry of Clinical Trials [Internet]. Havana: National Clinical Trials Coordinating Center (CU); c2014. Evaluación de la efi cacia y la seguridad del SURFACEN® en el tratamiento del Síndrome de Distress Respiratorio Agudo en edades pediátricas; 2016 Mar 29 [cited 2016 Aug 8]. Available from: http://rpcec .sld.cu/ensayos/RPCEC00000163-Sp/revisions/ view/2495/3688. Spanish.

  29. National Drugs Quality Control Center (CU). Protocolo de Investigación de EC fase III “Evaluación de la efi cacia y seguridad del Surfacén en el tratamiento del Síndrome de Distress Respiratorio en edades pediátricas”. Aprobado por el CECMED, el 16/11/2009 con número de referencia 05.005.09.B. Havana: National Drugs Quality Control Center (CU); 2009 Nov. Spanish.

  30. Garza Alatorre A, Hernández Rosales CD, Cantú Moreno D. Prevalencia del Síndrome de Difi cultad Respiratoria Aguda en una unidad de cuidados intensivos pediátrica polivalente. Med Univ. 2012 Jan;14(54):11–5. Spanish.

  31. Suresh GK, Soll RF. Pharmacologic Adjuncts II: Exogenous Surfactants. In: Goldsmith J, Karotkin E, editors. Assisted Ventilation of the Neonate. St. Louis: Saunders–Elsevier Inc.; 2011. p. 371–88.

  32. Willson DF, Notter RH. The future of exogenous surfactant therapy. Resp Care [Internet]. 2011 Sep [cited 2016 Apr 27];56(9):1369–88. Available from: http://rc.rcjournal.com/content /56/9/1369

  33. Spragg RG, Lewis JF, Walmrath HD, Johannigman J, Bellingan G, Laterre PF, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med [Internet]. 2004 Aug 26 [cited 2016 Apr 27];351(9):884–92. Available from: http:// discovery.ucl.ac.uk/8024/1/8024.pdf

  34. Rojas Medina JE, León Villanueva A, Molano M. Síndrome de difi cultad respiratoria aguda en pediatría. Acta Colombiana Cuidado Intensivo. 2010;10:213–26. Spanish.

  35. Ríos-Meléndez NA, Garza-Alatorre A. Uso del surfactante en el síndrome de difi cultad respiratoria aguda (SDRA) en pediatría. Med Univ. 2011 Jan;13(50):37–40. Spanish.

  36. Thomas NJ, Guardia CG, Moya FR, Cheifetz IM, Markovitz B, Cruces P, et al. A pilot, randomized, controlled clinical trial of lucinactant, a peptidecontaining synthetic surfactant, in infants with acute hypoxemic respiratory failure. Pediatr Crit Care Med [Internet]. 2012 Nov [cited 2016 Apr 27];13(6):646–53. Available from: https:// www.researchgate.net/profile/Pablo_Cruces/ publication/229082114_A_pilot_randomized _controlled_clinical_trial_of_lucinactant_a_pepti de-containing_synthetic_surfactant_in_infants _with_acute_hypoxemic_respiratory_failure/ links/00b49524862702cb76000000.pdf

  37. Costa EL, Amato MB. The new defi nition for acute lung injury and acute respiratory distress syndrome: is there room for improvement? Curr Opin Crit Care [Internet]. 2013 Feb [cited 2016 Jan 12];19(1):16–23. Available from: http://journals.lww.com/co-criticalcare/Abstract /2013/02000/The_new_defi nition for_acute_lung _injury_and_acute.4.aspx

  38. Rittayamai N, Brochard L. Recent advances in mechanical ventilation in patients with acute respiratory distress syndrome. Eur Respir Rev [Internet]. 2015 Mar [cited 2016 Apr 27];24(135):132–40. Available from: http://err .ersjournals.com/content/24/135/132.full

  39. Gargano G, Braibanti S. Lung recruitment strategy and surfactant in delivery room. Acta Biomed [Internet]. 2014 Jun 20 [cited 2016 Apr 27];85(1):7–10. Available from: https://www.ma ttioli1885journals.com/index.php/actabiomedica/ article/viewFile/3682/2649

  40. Speer CP, Sweet DG, Halliday HL. Surfactant therapy: past, present and future. Earl Hum Dev [Internet]. 2013 [cited 2016 Apr 27];89S1:S22– S24. Available from: https://linkinghub.elsevier .com/retrieve/pii/S0378-3782(13)70008-2

  41. Rodríguez-Moya VS, Quiroz-Viqueira O, Oliva de Céspedes CM, Díaz-Casañas E. Surfactante exógeno como tratamiento de la atelectasia pulmonar masiva. AMC [Internet]. 2015 Jul–Aug [cited 2016 Apr 27];19(4):374–80. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext &pid=S1025-02552015000400009. Spanish.

  42. Laughon M, Bose C, Moya F, Aschner J, Donn SM, Morabito C, et al. A pilot randomized, controlled trial of later treatment with a peptidecontaining, synthetic surfactant for the prevention of bronchopulmonary dysplasia. Pediatrics [Internet]. 2009 Jan [cited 2011 Aug];123(1):89–96. Available from: http://pediatrics.aappublications .org/content/123/1/89.full

  43. Gattinioni L, Carlesso E, Brazzi L, Caironi P. Positive end expiratory pressure. Curr Opin Crit Care. 2010 Feb;16(1):39–44.

  44. Pintado MC, de Pablo R. Aplicación individualizada de la presión positiva al fi nal de la espiración en pacientes con síndrome de distrés respiratorio agudo. Med Intensiva [Internet]. 2014 Nov [cited 2016 Jan 12];38(8):498–501. Available from: http://www.sciencedirect.com/science/article/pii/ S0210569113002544. Spanish.

  45. Keenan JC, Dries DJ. PEEP titration: new horizons. Respir Care [Internet]. 2013 Sep [cited 2016 Apr 27];58(9):1552–4. Available from: http:// rc.rcjournal.com/content/58/9/1552.short

  46. Kesecioglu J, Beale R, Stwart TE, Findlay GP, Rouby JJ, Holzapfel L, et al. Exogenus natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med [Internet]. 2009 Nov 15 [cited 2016 Jan 12];180(10):989–94. Available from: http://www.atsjournals.org/doi/full/10.1164/ rccm.200812-1955OC

  47. Walsh BK, Daigle B, DiBlasi RM, Restrepo RD; American Association for Respiratory Care. AARC Clinical Practice Guideline. Surfactant Replacement Therapy: 2013. Respir Care [Internet]. 2013 Feb [cited 2016 Jan 12];58(2):367–75. Available from: https://www.researchgate.net/ profile/Brian_Walsh8/publication/235381146_A ARC_Clinical_Practice_Guideline._Surfactant _Replacement_Therapy_2013/links/00b7d529b 741864f01000000.pdf

  48. Duffett M, Choong K, Ng V, Randolph A, Cook DJ. Surfactant therapy for acute respiratory failure in children: a systematic review and meta-analysis. Crit Care [Internet]. 2007 Jun 15 [cited 2016 Apr 27];11(3):R66. Available from: http://www .biomedcentral.com/1364-8535/11/R66

  49. Hong XY, Kong XY, Zhou GX, Liu YH, Yang XY, Feng ZC. [Effects of pulmonary surfactant in treatment of acute lung injury after cardiac surgery in infants]. Zhonghua Er Ke Za Zhi [Internet]. 2012 Mar [cited 2016 Jan 12];50(3):193–6. Available from: http://europepmc.org/abstract/ med/22801200. Chinese.




2020     |     www.medigraphic.com